• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Low dose of hydroxychloroquine is associated with reduced COVID-19 mortality: a multicenter study in China.

作者信息

He Wu, Xu Ke, Yan Yongcui, Li Gen, Yu Bo, Wu Junfang, Zhong Kaineng, Zhou Da, Wang Dao Wen

机构信息

Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan, 430030, China.

Health Commission of Hubei Province, Wuhan, 430079, China.

出版信息

Front Med. 2025 Apr;19(2):386-390. doi: 10.1007/s11684-025-1123-9. Epub 2025 Mar 4.

DOI:10.1007/s11684-025-1123-9
PMID:40035964
Abstract
摘要

相似文献

1
Low dose of hydroxychloroquine is associated with reduced COVID-19 mortality: a multicenter study in China.低剂量羟氯喹与降低新冠病毒疾病死亡率相关：一项中国的多中心研究
Front Med. 2025 Apr;19(2):386-390. doi: 10.1007/s11684-025-1123-9. Epub 2025 Mar 4.
2
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.低剂量羟氯喹治疗对 COVID-19 住院患者死亡率的影响：一项全国性观察研究，纳入 8075 名参与者。
Int J Antimicrob Agents. 2020 Oct;56(4):106144. doi: 10.1016/j.ijantimicag.2020.106144. Epub 2020 Aug 24.
3
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.纽约州 COVID-19 患者住院死亡率与羟氯喹或阿奇霉素治疗的关联。
JAMA. 2020 Jun 23;323(24):2493-2502. doi: 10.1001/jama.2020.8630.
4
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.羟氯喹在住院 COVID-19 患者中的应用与降低死亡率相关：来自意大利 CORIST 观察性多中心研究的结果。
Eur J Intern Med. 2020 Dec;82:38-47. doi: 10.1016/j.ejim.2020.08.019. Epub 2020 Aug 25.
5
Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis.新型冠状病毒肺炎危重症患者使用羟氯喹的90天生存率：一项倾向分析
Ann Transl Med. 2021 Apr;9(7):524. doi: 10.21037/atm-20-7811.
6
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.羟氯喹和托珠单抗治疗 COVID-19 患者：一项观察性研究。
PLoS One. 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693. eCollection 2020.
7
Efficacy of Hydroxychloroquine in Pre-exposure Severe Acute Respiratory Syndrome Coronavirus 2 Prophylaxis among High-Risk HealthCare Workers: A Multicenter Study.羟氯喹在高危医护人员暴露前预防严重急性呼吸综合征冠状病毒2中的疗效：一项多中心研究。
Adv Biomed Res. 2023 Jan 27;12:3. doi: 10.4103/abr.abr_104_21. eCollection 2023.
8
Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada.羟氯喹暴露前预防以保护一线医护人员免受 COVID-19 感染：一项在加拿大多伦多进行的随机安慰剂对照多中心试验的研究方案的结构化总结。
Trials. 2020 Jul 14;21(1):647. doi: 10.1186/s13063-020-04577-8.
9
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.羟氯喹低剂量可降低 COVID-19 重症患者的死亡率。
Sci China Life Sci. 2020 Oct;63(10):1515-1521. doi: 10.1007/s11427-020-1732-2. Epub 2020 May 15.
10
Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.ORCHID 研究的原理和设计：羟氯喹治疗 COVID-19 成年住院患者的随机安慰剂对照临床试验。
Ann Am Thorac Soc. 2020 Sep;17(9):1144-1153. doi: 10.1513/AnnalsATS.202005-478SD.

本文引用的文献

1
Wuhan 3 years after the outbreak of the pandemic-cardiological insights and perspectives.新冠疫情爆发三年后的武汉：心脏医学的洞察与展望。
Herz. 2023 Jun;48(3):173-179. doi: 10.1007/s00059-023-05176-4. Epub 2023 Apr 27.
2
Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patients.羟氯喹缩短了住院 COVID-19 患者的住院时间，并减少了重症监护病房的入院人数。
J Infect Dev Ctries. 2022 Jan 31;16(1):25-31. doi: 10.3855/jidc.14933.
3
Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality.
新冠病毒感染发病率、严重程度和死亡率的风险和保护因素。
Clin Rev Allergy Immunol. 2023 Feb;64(1):90-107. doi: 10.1007/s12016-022-08921-5. Epub 2022 Jan 19.
4
Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate.羟氯喹/阿奇霉素治疗 COVID-19：治疗时间与病死率的关系。
Travel Med Infect Dis. 2021 Nov-Dec;44:102163. doi: 10.1016/j.tmaid.2021.102163. Epub 2021 Sep 14.
5
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering.通过分层聚类解析羟氯喹治疗与 COVID-19 住院患者死亡率的关联。
J Healthc Eng. 2021 Jun 25;2021:5556207. doi: 10.1155/2021/5556207. eCollection 2021.
6
Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms.氯喹和羟氯喹在基于自噬相关机制的抗肿瘤治疗中的应用。
Pharmacol Res. 2021 Jun;168:105582. doi: 10.1016/j.phrs.2021.105582. Epub 2021 Mar 26.
7
Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment.对新冠病毒（COVID-19）羟氯喹治疗候选药物的初步数据进行平衡评估。
Int J Antimicrob Agents. 2021 Mar;57(3):106292. doi: 10.1016/j.ijantimicag.2021.106292.
8
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
9
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.羟氯喹治疗门诊轻度症状 COVID-19 患者：一项多中心观察性研究。
BMC Infect Dis. 2021 Jan 14;21(1):72. doi: 10.1186/s12879-021-05773-w.
10
Emerging treatment strategies for COVID-19 infection.针对 COVID-19 感染的新兴治疗策略。
Clin Exp Med. 2021 May;21(2):167-179. doi: 10.1007/s10238-020-00671-y. Epub 2020 Oct 30.